Biothreat Diagnostic Rapid Response
The following awards were made in support of the Biothreat Diagnostic Rapid Response (RPP-24-06-DxR2) initiative, which will facilitate rapid development and manufacturing capabilities for diagnostics that address the Public Health Emergency Medical Countermeasures Enterprise’s high-priority biothreats.
The overall goal of this program is to build a biothreat diagnostic portfolio, maintain domestic test manufacturing facilities and to enable just-in-time manufacturing practices to be able to rapidly produce biothreat tests at scale, or other tests needed by the US Government, along with the supplies needed, and to achieve aggressive test delivery schedules.
Award Details
Biothreat Diagnostic Rapid Response – Strategies and Solutions for Biothreat and Pandemic Response Readiness
Project Details
Member Organization: InBios International, Inc.
Award Date: 09/30/2024
Award Amount: $16,511,354
Project Duration: 36 Months
Solicitation Number: RPP-24-06-DxR2
Project Objective: InBios will build on their existing diagnostic device design. The project’s technical goal is to finalize the device’s testing workflow and algorithm and obtain FDA clearance.
Development of a Marburg Rapid Antigen Test
Project Details
Member Organization: OraSure Technologies, Inc.
Award Date: 11/26/2024
Award Amount: $7,553,929
Project Duration: 54 Months
Solicitation Number: RPP-24-06-DxR2
Project Objective: The objective of this project is to develop, design transfer, and manufacture an assay for the OraSure Marburg rapid test to allow for product sustainability and production-ready capacity by leveraging existing manufacturing capability of resources, processes, equipment, and facilities.
